炎症在许多癌症类型的发病机制中起着重要作用，并与甲状腺恶性肿瘤相关。全血细胞计数（CBC）可以计算出一种名为全身免疫炎症指数（SII）的新型炎症标志物。本研究调查了SII这一个源于常规CBC的标记物与不同甲状腺疾病之间的关联。目的在于确定这一简单的炎症标志物是否能够区分良性和恶性甲状腺疾病。系统评估了2018年1月至2022年1月间进行甲状腺疾病手术治疗的所有患者的病历。记录了术前常规CBC参数的人口统计学、临床和实验室数据。研究纳入了241名患者，并根据病理结果将患者分为多结节性甲状腺肿（n = 125）、淋巴细胞性甲状腺炎（n = 44）和乳头状甲状腺癌（PTC）（n = 73）组。SII定义为中性粒细胞总数×血小板数除以淋巴细胞数的比值。根据肿瘤的滤泡变异或甲状腺炎的存在、微小或巨大癌变以及肿瘤的双侧性，对患者进行了亚组分析。PTC组的SII水平显著高于淋巴细胞性甲状腺炎组和多结节性甲状腺肿组（P < .001）。将患者根据PTC的存在分为良性或恶性两组时，SII水平的最佳截断点为654.13，敏感性为73.8%，特异性为72.3%。在对PTC患者进行亚组分析时，SII水平在肿瘤的临床病理特征上相似。对甲状腺疾病的鉴别诊断对患者管理十分重要。我们发现术前SII水平在PTC患者中明显升高，与良性甲状腺疾病患者相比，这一简单标志物可用于良恶性甲状腺疾病的鉴别。版权所有 © 2023 作者(Wolters Kluwer Health, Inc.发表)

Inflammation plays an important role in the pathogenesis of many cancer types and is associated with thyroid malignancy. The systemic immune-inflammation index (SII) is a new inflammation marker that can be calculated from routine complete blood count (CBC). This study investigated the association between SII, a marker derived from routine CBC, and different thyroid diseases. The objective was to determine if this simple inflammation marker can distinguish between benign and malignant thyroid diseases. The medical records of all patients who underwent surgical treatment for thyroid disease between January 2018 and January 2022 were systematically evaluated. The routine preoperative CBC parameters' demographic, clinical, and laboratory data were recorded. A total of 241 patients were included in the study, and the patients were grouped as having multinodular goiter (n = 125), lymphocytic thyroiditis (n = 44), and papillary thyroid carcinoma (PTC) (n = 73) according to pathological results. The SII was defined as the ratio of the total count of neutrophils × platelets divided by the lymphocyte count. Subgroup analysis of patients was performed according to the presence of follicular variant or thyroiditis, micro or macro carcinoma, or bilaterality of the tumor. The SII level was significantly higher in the PTC group than in the lymphocytic thyroiditis and multinodular goiter groups (P < .001). When we grouped the patients according to the presence of PTC as benign or malignant, the optimum cutoff point for SII level was found 654.13, with 73.8% sensitivity and 72.3% specificity from ROC analysis. In the subgroup analysis of patients with PTC, the SII level was similar according to the clinicopathological characteristics of the tumor. The differential diagnosis of thyroid diseases is important for patient management. We found that preoperative SII levels were significantly elevated in patients with PTC compared to those with benign thyroid disorders, and this simple marker can be used for the differentiation of benign and malignant thyroid disease.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.